Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 30;14(11):e0008847.
doi: 10.1371/journal.pntd.0008847. eCollection 2020 Nov.

The economic burden of dengue fever in the Kingdom of Saudi Arabia

Affiliations

The economic burden of dengue fever in the Kingdom of Saudi Arabia

Naeema A Akbar et al. PLoS Negl Trop Dis. .

Abstract

Rapid urbanization, global trade, and the exceptionally great numbers of worldwide visitors during Hajj and Umrah have all placed the Kingdom of Saudi Arabia at a significant risk of introducing several vector-borne tropical diseases, such as dengue fever virus (DENV) infection. In this study we estimated DENV infection cost of illness (COI) in Saudi Arabia in the period 2013-2017, by processing national data including all declared cases recorded in referral centers in the western region, being the endemic region of the country. Using a statistically validated predictive model that was built on a representative sample of 717 laboratory-confirmed cases of DENV infection, direct costs, due to care-related expenditures, were estimated by applying the predictive equation to national data. However, indirect costs, which are due to productivity loss, were estimated using the human capital model based on gross domestic product adjusted for invalidity duration. Further, under-reporting was adjusted by using an expansion factor EF = 3. We observed highest estimated costs in 2016 with over US$168.5 Million total costs, including direct (US$29.0 Million) and indirect (US$139.5 Million) costs, for a total 4415 confirmed cases. The total DENV COI for the five years was estimated as US$551.0 Million for a total 15,369 patients (59.7%) out of 25,745 declared cases, resulting in an average cost of US$11 947.6 by patient. Depending on the year, productivity years loss costs accounted for 63.3% to 83.8% of the estimated total costs. Dengue has a substantial local economic burden that costs US$110.2 Million per year, stressing the urgent need for an effective national prevention strategy to perform considerable cost-savings besides reducing morbidity.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist

Figures

Fig 1
Fig 1. Estimation of dengue hemorrhagic fever cost of illness by estimating Direct Costs using Bottom-Up approach and Indirect Costs using Human Capital Model (Akbar et al, 2020).
Fig 2
Fig 2. Estimated direct and indirect costs of dengue fever in Saudi Arabia during the period 2013–2017.
Bars represent the amount in US$ of the (a) estimated direct and indirect costs by year, and (b) different components of indirect costs including costs related to daily activity loss (DALS), caregiver daily activity loss (CG-DALS) and productivity years loss (PYLS).

Similar articles

  • Diversity of dengue virus-3 genotype III in Jeddah, Saudi Arabia.
    Hashem AM, Sohrab SS, El-Kafrawy SA, Abd-Alla AMM, El-Ela SA, Abujamel TS, Hassan AM, Farraj SA, Othman NA, Charrel RN, Azhar EI. Hashem AM, et al. Acta Trop. 2018 Jul;183:114-118. doi: 10.1016/j.actatropica.2018.04.002. Epub 2018 Apr 3. Acta Trop. 2018. PMID: 29621534
  • Multiple Introductions of Dengue 2 Virus Strains into Saudi Arabia from 1992 to 2014.
    El-Kafrawy SA, Sohrab SS, Ela SA, Abd-Alla AM, Alhabbab R, Farraj SA, Othman NA, Hassan AM, Bergoin M, Klitting R, Charrel RN, Hashem AM, Madani TA, Azhar EI. El-Kafrawy SA, et al. Vector Borne Zoonotic Dis. 2016 Jun;16(6):391-9. doi: 10.1089/vbz.2015.1911. Epub 2016 May 2. Vector Borne Zoonotic Dis. 2016. PMID: 27135750 Free PMC article.
  • Economic burden of dengue in Indonesia.
    Nadjib M, Setiawan E, Putri S, Nealon J, Beucher S, Hadinegoro SR, Permanasari VY, Sari K, Wahyono TYM, Kristin E, Wirawan DN, Thabrany H. Nadjib M, et al. PLoS Negl Trop Dis. 2019 Jan 10;13(1):e0007038. doi: 10.1371/journal.pntd.0007038. eCollection 2019 Jan. PLoS Negl Trop Dis. 2019. PMID: 30629593 Free PMC article.
  • Economic burden of dengue infections in India.
    Garg P, Nagpal J, Khairnar P, Seneviratne SL. Garg P, et al. Trans R Soc Trop Med Hyg. 2008 Jun;102(6):570-7. doi: 10.1016/j.trstmh.2008.02.015. Epub 2008 Apr 9. Trans R Soc Trop Med Hyg. 2008. PMID: 18402995 Review.
  • Economic cost and burden of dengue during epidemics and non-epidemic years in Taiwan.
    Luh DL, Liu CC, Luo YR, Chen SC. Luh DL, et al. J Infect Public Health. 2018 Mar-Apr;11(2):215-223. doi: 10.1016/j.jiph.2017.07.021. Epub 2017 Jul 27. J Infect Public Health. 2018. PMID: 28757293 Review.

Cited by

References

    1. World Health Organization, UNICEF. Global vector control response 2017–2030. Available from: https://bit.ly/2DfuxHQ
    1. World Health Organization. Dengue and severe dengue Geneva: World Health Organization; 2018. [cited 2018 December 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
    1. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2018. [cited 2018 December 25]. Available from: http://ghdx.healthdata.org/gbd-results-tool.
    1. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(6):712–23. 10.1016/S1473-3099(16)00026-8 - DOI - PMC - PubMed
    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. 10.1038/nature12060 - DOI - PMC - PubMed

Publication types

Grants and funding

This study was funded by Sanofi Pasteur (Lyon, France) under the registration number Clinical Trial – DNG19-EXT to NA and OS.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.